DDInter1141 DDInter1070
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
Megestrol acetate {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Linagliptin
Megestrol acetate {u} (Compound) resembles {v} (Compound) Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Megestrol acetate {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Megestrol acetate {u} (Compound) resembles {v} (Compound) Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Megestrol acetate {u} (Compound) resembles {v} (Compound) Fludrocortisone
Fludrocortisone {u} (Compound) causes {v} (Side Effect) Diabetic
Diabetic {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Megestrol acetate {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Linagliptin
Megestrol acetate {u} (Compound) resembles {v} (Compound) Difluprednate
Difluprednate {u} (Compound) resembles {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linagliptin
Megestrol acetate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Linagliptin (Compound)
Megestrol acetate (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Megestrol acetate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Megestrol acetate (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Megestrol acetate (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone (Compound) causes Diabetic (Side Effect) and Diabetic (Side Effect) is caused by Linagliptin (Compound)
Megestrol acetate (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Megestrol acetate (Compound) resembles Difluprednate (Compound) and Difluprednate (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Linagliptin